Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines

Table 2 Correlation of clinicopathological and demographic parameters of CRC patients with cholinergic markers

Parameters	No. of cases	Percentage (%)	α7nAChR expression Low High		P values
Total	91	100	49 (53.8%)	42 (46.2%)
Gender Male Female	51 40	56.0 44.0	30 (33.0%) 19 (20.9%)	21 (23.1%) 21 (23.1%)	0.194
Age <65 >65	41 50	45.1 54.9	24 (26.4%) 25 (27.5%)	17 (18.7%) 25 (27.5%)	0.274
Stage I + II III + IV	14 33	15.4 36.3	30 (33.0%) 19 (20.9%)	19 (20.9%) 23 (25.3%)	0.094
Parameters	No. of cases	Percentage (%)	M3R expression Low High		Pvalues
Total	91	100	58 (63.7%)	33 (36.3%)
Gender Male Female	51 40	56.0 44.0	31 (34.1%) 27 (29.7%)	20 (22.0%) 13 (14.3%)	0.508
Age <65 >65	41 50	45.1 54.9	22 (24.2%) 36 (39.6%)	19 (20.9%) 14 (15.4%)	0.070
Stage I + II III + IV	49 42	53.8 46.2	38 (41.8%) 11 (12.1%)	11 (12.1%) 31 (34.1%)	0.017
Parameters	No. of cases	Percentage (%)	ChAT expression Low High		Pvalues
Total	91	100	32 (35.2%)	59 (64.8%)
Gender Male Female	51 40	56.0 44.0	30 (33.0%) 19 (20.9%)	21 (23.1%) 21 (23.1%)	0.194
Age <65 >65	41 50	45.1 54.9	24 (26.4%) 25 (27.5%)	17 (18.7%) 25 (27.5%)	0.274
Stage I + II III + IV	49 42	53.8 46.0	30 (33.0%) 14 (15.4%)	19 (20.9%) 28 (30.6%)	0.049

P values are based on the frequency of cholinergic markers within each parameter

ISSN: 1471-2407